BioWorld

Nov. 20, 2007

Celgene's $2.9B For Pharmion Nets Hematology, Cancer Lines

Celgene Corp. is acquiring Pharmion Corp. for $2.9 billion in a cash and stock deal that will expand the Summit, N.J.-based biotech's presence in the global hematology and oncology markets. (BioWorld Today) Read More

No Surprise As Onyx's Nexavar Wins Approval In Liver Cancer

Speedel, Novartis In Dispute On Flow Of Aliskiren Data

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Dorsal striatum and its neurons in Huntington's disease

Anle-138b reduces mHTT aggregation, improves pathological phenotypes in Huntington’s models

BioWorld Science

Anle-138b (emrusolmin) is a diphenylpyrazole compound that directly interacts with oligomeric species of disease-related aggregating proteins, reducing aggregate...